BENGALURU – Indian pharmaceutical company Zydus said on Wednesday it has started human studies for its potential COVID-19 vaccine, as coronavirus infections continue to surge in the world’s third worst-hit nation.
ZyCoV-D, its plasmid DNA vaccine, was found to be safe, immunogenic and well-tolerated in the pre-clinical toxicity studies, Zydus said here
In the human trials, Zydus will enrol over 1,000 subjects across multiple clinical study sites in India.
July 15, 2020
Reporting by Chandini Monnappa in Bengaluru, Editing by Sherry Jacob-PhillipsOur Standards:The Thomson Reuters Trust Principles.
Categories: Health News